Lebedeva Natalya Valerievna

Lebedeva Natalya Valerievna

Biography

2022: Appointment to the position of CEO of Angiolaine

In June 2022, it became known about the appointment of Natalia Lebedeva as the new general director of Angiolain. The change of chapter came amid a corporate conflict within the manufacturer of medical devices for interventional cardiac surgery.

Earlier, the founders of Angiolain, Andrei Kudryashov and Alexei Frantsev, were expelled from the shareholders by decision of the Arbitration Court of the Novosibirsk Region. In total, entrepreneurs owned almost three quarters of the company's shares (37.2% each).

During the proceedings, the court considered that Kudryashov and the French caused significant harm to the company during the corporate conflict in 2017-2022. As RBC wrote, Lebedeva stated that she was removed from decision-making, and the actions of other shareholders had the goal of reducing her share in JSC (25%). She received shares in return for investments in 2013.

In mid-May 2022, the Supreme Court of the Russian Federation refused to Andrei Kudryashov and Alexei Frantsuzov to transfer to the Judicial Board for Economic Disputes a cassation appeal against the decision of lower instances that declared illegal the withdrawal of the main asset - the production company Angiolain Intervenshional Devices - from JSC to legal entities controlled by Kudryashov and Frantsuzov (Latrek LLC, Hart Invest LLC and Evron LLC). According to the judges of the RF Armed Forces, the deal bore the signs of a "pretend" and pursued the ultimate goal of withdrawing assets during a corporate conflict with another shareholder of the company, Natalya Lebedeva.

In June 2022, it became known that Angiolaine had stopped the production of medical devices for cardiac surgery. According to Natalia Lebedeva (BFM-Novosibirsk contacted her), as general director of the company, she will restart the enterprise "in the next short time."^[1]

Notes

Шаблон:Remarks